



Berkshire West Area Prescribing Committee Policy Statement

| | |
|--|---|
| Drug Name | Mesalazine (Salofalk®) |
| Indication under review | To induce and maintain remission in chronic inflammatory bowel disease – ulcerative colitis (UC) and Crohn's disease (CD) |
| Policy No: | APC 141 |
| Date of Issue: | January 2017 |
| Review Date: | January 2020 |
| Policy Statement: Salofalk® is a brand of mesalazine which has been considered appropriate to add to the joint formulary for the induction and maintenance of remission in chronic inflammatory bowel disease. | |
| Traffic Light Status | Green |
| Key Points considered: <ul style="list-style-type: none">• Mesalazine is an aminosalicylate that is used routinely to induce and maintain remission in chronic inflammatory bowel disease – ulcerative colitis (UC) and Crohn's disease.• A review of oral aminosalicylate formulations for ulcerative colitis in the Drug & Therapeutics Bulletin in January 2011 concluded that there is very little difference in terms of efficacy between mesalazine preparations so choice should depend on factors that may aid adherence to therapy; for example, less frequent dosing has been shown for some preparations to be as effective as multiple daily dosing. | |
| Date taken to APC: | 11 th January 2017 |
| Date Ratified by GPMOC on Behalf of the Board: | 18 th January 2017 |